Rockefeller Capital Management’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Rockefeller Capital Management’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$175K	Buy	5,189 +1,699	+49%	+$51K	﹤0.01%	2676
2026 Q1	$101K	Buy	3,490 +1,168	+50%	+$33.9K	﹤0.01%	2865
2025 Q4	$60.8K	Buy	2,322 +251	+12%	+$6.46K	﹤0.01%	2981
2025 Q3	$48.9K	Buy	+2,071	New	+$45.8K	﹤0.01%	2929
2023 Q1	–	Sell	-2,504	Closed	-$63K	–	2882
2022 Q4	$63K	Sell	2,504 -80	-3%	-$2.15K	﹤0.01%	2265
2022 Q3	$68K	Buy	2,584 +2,078	+411%	+$64.1K	﹤0.01%	2198
2022 Q2	$14K	Sell	506 -16,086	-97%	-$480K	﹤0.01%	2941
2022 Q1	$571K	Buy	16,592 +430	+3%	+$15.2K	﹤0.01%	1272
2021 Q4	$708K	Buy	16,162 +3	+0%	+$142	﹤0.01%	1186
2021 Q3	$819K	Hold	16,159	–	–	﹤0.01%	1072
2021 Q2	$840K	Buy	16,159 +15,209	+1,601%	+$714K	﹤0.01%	999
2021 Q1	$43K	Buy	+950	New	+$46.4K	﹤0.01%	1949

Other funds holding IDNA

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $1.05B AUM 18.22% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Trek Financial Scottsdale, Arizona $2.01B AUM 53.49% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Rockefeller Capital Management's IDNA Position: Q2 2026 in Review

Rockefeller Capital Management increased its iShares Genomics Immunology and Healthcare ETF (IDNA) stake by 49% in Q2 2026, buying an estimated $51K and bringing the position to 5,189 shares worth $175K. The position accounts for ﹤0.01% of the portfolio, ranked #2676.

Rockefeller Capital Management first reported a position in IDNA in Q1 2021 and has held it in 12 quarters since. The position peaked at $840K in Q2 2021. 66 funds tracked by Wall St. Rank hold IDNA as of Q2 2026.

Rockefeller Capital Management held 5,189 shares of iShares Genomics Immunology and Healthcare ETF worth $175K as of Q2 2026.
Rockefeller Capital Management bought 1,699 iShares Genomics Immunology and Healthcare ETF shares in Q2 2026, an estimated $51K.
iShares Genomics Immunology and Healthcare ETF made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #2676 holding.
Rockefeller Capital Management first reported a position in iShares Genomics Immunology and Healthcare ETF in Q1 2021 and has held it in 12 quarters since.
Rockefeller Capital Management's iShares Genomics Immunology and Healthcare ETF position peaked at $840K in Q2 2021.
66 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.